Kameda, Hideto http://orcid.org/0000-0002-4330-5782
Hirata, Ayako
Katagiri, Takaharu
Takakura, Yuto
Inoue, Yuki
Takenaka, Sayaka
Ito, Hideki
Mizushina, Kennosuke
Ogura, Takehisa
Funding for this research was provided by:
the Ministry of Health, Labour and Welfare of Japan (Health and Labour Sciences Research Grants for research on intractable diseases (The Research Team for Autoimmune Diseases))
JSPS KAKENHI (JP15K09535)
Article History
Received: 13 November 2020
Accepted: 8 March 2021
First Online: 25 March 2021
Competing interests
: This work was partly supported by JSPS KAKENHI Grant Number JP15K09535, Health and Labour Sciences Research Grants for research on intractable diseases (The Research Team for Autoimmune Diseases) from the Ministry of Health, Labour and Welfare of Japan for H.K. H.K. has received consulting fees, speaking fees, and/or honoraria from AbbVie G.K., Asahi Kasei Pharma, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Gilead Sciences, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Novartis Pharma K.K., and Sanofi Pharma; and has received research grants from AbbVie G.K., Asahi Kasei Pharma, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma, Novartis Pharma K.K., and Sanofi Pharma. T.O. has received honoraria from AbbVie G.K. A.H., T.K., Y.T., Y.I., S.T., H.I. and K.M. declare no potential conflict of interest.